Phase II/III Trial of MEDI4736 (Durvalumab) and Chemotherapy for Patients with High Grade Upper Tract Urothelial Cancer Prior to Nephroureterectomy

Study chair Jean Hoffman-Censits, MD (Johns Hopkins University/The Sidney Kimmel Comprehensive Cancer Center), and co-chairs Petros Grivas, MD, PhD (University of Washington/Fred Hutchinson Cancer Research Center), and Vitaly Margulis, MD (UT Southwestern Medical Center/Simmons Cancer Center), review the goals and potential impact of EA8192. Noah Hahn, MD (Johns Hopkins University/The Sidney Kimmel Comprehensive Cancer Center), moderates the discussion. Watch the video below or on the ECOG-ACRIN YouTube Channel.

Learn more about EA8192 at ecog-acrin.org.